Search results
Results from the WOW.Com Content Network
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States , South America , Asia , and Europe . BioMarin's core business and research is in enzyme replacement therapies (ERTs).
During his tenure at BioMarin, Kakkis guided the development and approval of two more treatments for rare disorders, MPS VI and PKU and has contributed to the initiation of seven other treatment programs for rare disorders, three of which are now in clinical development. Kakkis is board certified in both Pediatrics and Medical Genetics.
Ultragenyx Pharmaceutical Inc. was founded in 2010 by Emil Kakkis based on his history of developing therapies for rare disease starting at Harbor-UCLA Medical Center, continuing through his role as chief medical officer of BioMarin and as founder of the EveryLife Foundation. [11]
(Reuters) - BioMarin Pharmaceutical has received a subpoena from the U.S. Department of Justice seeking information about the company's sponsored testing programs related to two treatments, the ...
Orphan drug specialist BioMarin Pharmaceutical enjoyed a notable week. It started with the U.S. Food and Drug Administration, or FDA, officially approving the company's enzyme replacement therapy ...
For premium support please call: 800-290-4726 more ways to reach us
The combination of the two companies created one of the world's top 10 pharmaceutical companies by revenue and a leader in a new industry model. [34] As of March 15, 2015, Valeant's stock crashed more than 50%. [35] A number of factors contributed to the collapse of Valeant, many of which validate Pyott's approach to business. [36]
For premium support please call: 800-290-4726 more ways to reach us